| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Yuyu Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,845.00 |
| 52 Week High | ₩11,020.00 |
| 52 Week Low | ₩4,010.00 |
| Beta | 0.56 |
| 11 Month Change | -4.81% |
| 3 Month Change | -7.89% |
| 1 Year Change | -12.55% |
| 33 Year Change | -67.70% |
| 5 Year Change | 34.02% |
| Change since IPO | 297.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| A000225 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -0.9% | 7.0% | 2.2% |
| 1Y | -12.5% | 20.0% | 11.0% |
Return vs Industry: A000225 underperformed the KR Pharmaceuticals industry which returned 20% over the past year.
Return vs Market: A000225 underperformed the KR Market which returned 11% over the past year.
Price Volatility
| A000225 volatility | |
|---|---|
| A000225 Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A000225 has not had significant price volatility in the past 3 months.
Volatility Over Time: A000225's weekly volatility has decreased from 9% to 3% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 318 | Robert Yu | www.yuyu.co.kr |
Yuyu Pharma, Inc. develops and markets pharmaceutical products. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Jecheon-si, South Korea.
Yuyu Pharma, Inc. Fundamentals Summary
| A000225 fundamental statistics | |
|---|---|
| Market cap | ₩75.73b |
| Earnings (TTM) | -₩2.06b |
| Revenue (TTM) | ₩136.32b |
0.6x
P/S Ratio-36.8x
P/E RatioIs A000225 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A000225 income statement (TTM) | |
|---|---|
| Revenue | ₩136.32b |
| Cost of Revenue | ₩87.44b |
| Gross Profit | ₩48.88b |
| Other Expenses | ₩50.94b |
| Earnings | -₩2.06b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -127.00 |
| Gross Margin | 35.86% |
| Net Profit Margin | -1.51% |
| Debt/Equity Ratio | 28.2% |
How did A000225 perform over the long term?
See historical performance and comparison